Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

4.550 -0.220 (-4.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,992,290
Open 4.800
Bid (Size) 4.500 (2)
Ask (Size) 4.600 (1)
Prev. Close 4.770
Today's Range 4.545 - 4.800
52wk Range 3.095 - 6.630
Shares Outstanding 220,750,928
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
Analyst Ratings for Immunogen
 
Via Benzinga

Performance

YTD
-4.61%
-4.61%
1 Month
+9.90%
+9.90%
3 Month
-20.18%
-20.18%
6 Month
-13.66%
-13.66%
1 Year
-17.72%
-17.72%

More News

Read More
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
From ImmunoGen, Inc.
Via Business Wire
Analyst Ratings for Immunogen
Via Benzinga
6 Analysts Have This to Say About Immunogen
Via Benzinga
What 6 Analyst Ratings Have To Say About Immunogen
Via Benzinga
Looking Into Immunogen's Return On Capital Employed
Via Benzinga
What You Missed On Wall Street On Friday
Via Talk Markets
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
Via Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
From ImmunoGen, Inc.
Via Business Wire
After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
Via Benzinga
Expert Ratings for Immunogen
Via Benzinga
ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
Via Benzinga
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Via Talk Markets
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
From ImmunoGen, Inc.
Via Business Wire
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
Via Benzinga
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
From ImmunoGen, Inc.
Via Business Wire
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.